

# Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

**f** [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT\\_INFO.CFM?PRODUCT\\_NO=001&APPL\\_NO=207620&APPL\\_TYPE=N\)](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?product_no=001&appl_no=207620&appl_type=N)

**t** [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT\\_INFO.CFM?PRODUCT\\_NO=001&APPL\\_NO=207620&APPL\\_TYPE=N\)](https://twitter.com/intent/tweet?text=ORANGE%20BOOK:%20APPROVED%20DRUG%20PRODUCTS%20WITH%20THERAPEUTIC%20EQUIVALENCE%20EVALUATIONS&url=https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?product_no=001&appl_no=207620&appl_type=N)

**±**

**✉** [EMAIL \(MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT\\_INFO.CFM?PRODUCT\\_NO=001&APPL\\_NO=207620&APPL\\_TYPE=N\)](mailto:?subject=ORANGE%20BOOK:%20APPROVED%20DRUG%20PRODUCTS%20WITH%20THERAPEUTIC%20EQUIVALENCE%20EVALUATIONS&body=https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?product_no=001&appl_no=207620&appl_type=N)

[Home \(index.cfm?resetfields=1\)](#) | [Back to Product Details](#)

## Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53 (d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

## Patent and Exclusivity for: N207620

Product 001

SACUBITRIL; VALSARTAN (ENTRESTO) TABLET 24MG;26MG

### Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submit Date
001	7468390	11/27/2023		DP			08/06/20
001	7468390*PED	05/27/2024					
001	8101659	01/14/2023		DP			08/06/20
001	8101659*PED	07/14/2023					
001	8404744	01/14/2023		DP			08/06/20
001	8404744*PED	07/14/2023					
001	8796331	01/14/2023			U-1723		08/06/20
001	8796331*PED	07/14/2023					
001	8877938	05/27/2027	DS	DP			08/06/20
001	8877938*PED	11/27/2027					
001	9388134	11/08/2026			U-1723		09/07/20
001	9388134*PED	05/08/2027					

#### Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration
001	NCE	07/07/2020
001	NCE *PED	01/07/2021
001	NPP	10/01/2022
001	NPP *PED	04/01/2023

&lt;

&gt;

[View a list of all patent use codes \(results\\_patent.cfm\)](#)

[View a list of all exclusivity codes \(results\\_exclusivity.cfm\)](#)